It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALVO’s FA Score shows that 0 FA rating(s) are green whileEAPIF’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALVO’s TA Score shows that 4 TA indicator(s) are bullish while EAPIF’s TA Score has 2 bullish TA indicator(s).
ALVO (@Pharmaceuticals: Generic) experienced а +9.09% price change this week, while EAPIF (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.58%. For the same industry, the average monthly price growth was -3.79%, and the average quarterly price growth was +30.64%.
ALVO is expected to report earnings on Apr 01, 2026.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| ALVO | EAPIF | ALVO / EAPIF | |
| Capitalization | 1.72B | 371M | 464% |
| EBITDA | 207M | -37.9M | -546% |
| Gain YTD | -58.277 | 19.667 | -296% |
| P/E Ratio | 24.00 | 7.92 | 303% |
| Revenue | 560M | 883M | 63% |
| Total Cash | 151M | 57.8M | 261% |
| Total Debt | 1.27B | 68.4M | 1,854% |
| ALVO | EAPIF | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 59% | N/A |
| Stochastic ODDS (%) | 1 day ago 50% | 1 day ago 11% |
| Momentum ODDS (%) | 1 day ago 56% | N/A |
| MACD ODDS (%) | 1 day ago 56% | 1 day ago 38% |
| TrendWeek ODDS (%) | 1 day ago 56% | 1 day ago 36% |
| TrendMonth ODDS (%) | 1 day ago 65% | 1 day ago 33% |
| Advances ODDS (%) | 3 days ago 64% | N/A |
| Declines ODDS (%) | 11 days ago 68% | N/A |
| BollingerBands ODDS (%) | 1 day ago 69% | N/A |
| Aroon ODDS (%) | 1 day ago 68% | 1 day ago 23% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| DFEMX | 36.89 | -0.32 | -0.86% |
| DFA Emerging Markets I | |||
| OEPIX | 80.33 | -1.43 | -1.75% |
| Oil Equipment&Svcs UltraSector Pro Inv | |||
| ESMAX | 16.63 | -0.38 | -2.23% |
| Invesco Global Small Cap Equity A | |||
| TQMIX | 18.65 | -0.45 | -2.36% |
| AMG TimesSquare Mid Cap Growth I | |||
| MSGLX | 12.91 | -0.43 | -3.22% |
| MassMutual Small Cap Gr Eq Adm | |||
A.I.dvisor tells us that ALVO and EBS have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALVO and EBS's prices will move in lockstep.
| Ticker / NAME | Correlation To ALVO | 1D Price Change % | ||
|---|---|---|---|---|
| ALVO | 100% | -1.43% | ||
| EBS - ALVO | 29% Poorly correlated | -4.53% | ||
| CRON - ALVO | 27% Poorly correlated | -2.36% | ||
| PAHC - ALVO | 26% Poorly correlated | -1.37% | ||
| VTRS - ALVO | 22% Poorly correlated | -0.91% | ||
| ACB - ALVO | 22% Poorly correlated | -3.09% | ||
More | ||||
A.I.dvisor tells us that EAPIF and HLN have been poorly correlated (+14% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EAPIF and HLN's prices will move in lockstep.
| Ticker / NAME | Correlation To EAPIF | 1D Price Change % | ||
|---|---|---|---|---|
| EAPIF | 100% | N/A | ||
| HLN - EAPIF | 14% Poorly correlated | +0.20% | ||
| HLNCF - EAPIF | 11% Poorly correlated | N/A | ||
| IXHL - EAPIF | 7% Poorly correlated | -4.16% | ||
| AKAN - EAPIF | 2% Poorly correlated | -3.01% | ||
| ALVO - EAPIF | 2% Poorly correlated | -1.43% | ||
More | ||||